SY-13380 / Shouyao Holdings - LARVOL DELTA

SY-13380, a novel menin-MLL inhibitor, exhibits efficacy against resistant mutations and anti-tumor activity for MLL-rearranged and NPM1-mutant acute myeloid leukemia in pre-clinical models (AACR 2025) - "However, early trials with revumenib have reported the rapid acquisition of resistance somatic mutations of MEN1 gene in about 40% patients which can impair treatment success. In addition, SY-13380 displayed good PK parameters and tolerability in vitro and in vivo models. These data indicate that SY-13380 is a novel and potent menin-MLL inhibitor with robust anti-tumor activities, favorable PK and safety profiles making it promising for further clinical development and efficacy against resistant mutations warranting it long-term response for treatment of MLL-r and NPM1m acute leukemias."

Preclinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • HOXA9 • ITGAM • KMT2A • MEIS1 • MEN1 • NPM1